Brief: Clearside Biomedical Opens Enrollment In Odyssey Phase 2B Clinical Trial Of Cls-Ax (Axitinib Injectable Suspension) In Wet AMD
01/06/2023 12:52
June 1 (Reuters) - Clearside Biomedical Inc CLSD.O :
* CLEARSIDE BIOMEDICAL OPENS ENROLLMENT IN ODYSSEY PHASE 2B
CLINICAL TRIAL OF CLS-AX (AXITINIB INJECTABLE SUSPENSION) IN WET
AMD
* CLEARSIDE BIOMEDICAL INC - ODYSSEY TOPLINE RESULTS
EXPECTED IN
Q3 2024
* CLEARSIDE BIOMEDICAL INC - ODYSSEY TOPLINE RESULTS
EXPECTED IN
Q3 2024
Source text for Eikon: ID:nGNX3y52T5
Further company coverage: CLSD.O
Recent news on Clearside Biomedical,
See all newsBrief: Clearside Biomedical Completes Financial Restructuring And Emerges From Chapter 11 With Steel Partners As Plan Sponsor
U.S. STOCKS ON THE MOVE-Merck, Genco, Tesla
U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
Clearside Biomedical plunges after filing for Chapter 11 bankruptcy
U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials